Net Income (Loss) Attributable to Parent in USD of Sigyn Therapeutics, Inc. from Q3 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Sigyn Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q3 2014 to Q3 2025.
  • Sigyn Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$578,503.000, a 51.7% increase year-over-year.
  • Sigyn Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$3,221,072.000, a 19.3% increase year-over-year.
  • Sigyn Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$3,340,212.000, a 19.4% increase from 2023.
  • Sigyn Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$4,145,936.000, a 41.5% decline from 2022.
  • Sigyn Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$2,929,817.000, a 2.49% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Sigyn Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$3,221,072 -$578,503 +$618,420 +51.7% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$3,839,492 -$1,451,187 -$588,804 -68.3% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$3,250,688 -$668,564 +$89,524 +11.8% 01 Jan 2025 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$3,340,212 -$522,818 +$653,232 +55.5% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$3,993,444 -$1,196,923 -$291,197 -32.2% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$3,702,247 -$862,383 -$139,259 -19.3% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$3,562,988 -$758,088 +$582,948 +43.5% 01 Jan 2024 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$4,145,936 -$1,176,050 -$317,113 -36.9% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$3,828,823 -$905,726 -$179,217 -24.7% 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024
Q2 2023 -$3,649,606 -$723,124 -$56,799 -8.5% 01 Apr 2023 30 Jun 2023 10-Q 19 Nov 2024
Q1 2023 -$3,592,807 -$1,341,036 -$662,990 -97.8% 01 Jan 2023 31 Mar 2023 10-Q 19 Nov 2024
Q4 2022 -$2,929,817 -$858,937 +$368,235 +30% 01 Oct 2022 31 Dec 2022 10-K 20 Feb 2024
Q3 2022 -$3,298,052 -$726,509 -$60,605 -9.1% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$3,237,447 -$666,325 -$16,464 -2.5% 01 Apr 2022 30 Jun 2022 10-Q 14 Nov 2023
Q1 2022 -$3,220,983 -$678,046 -$216,364 -46.9% 01 Jan 2022 31 Mar 2022 10-Q 14 Nov 2023
Q4 2021 -$3,004,619 -$1,227,172 -$775,150 -1.7% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$2,229,469 -$665,904 -$369,914 -1.2% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$1,859,555 -$649,861 -$389,465 -1.5% 01 Apr 2021 30 Jun 2021 10-Q 14 Nov 2022
Q1 2021 -$1,470,090 -$461,682 -$210,500 -83.8% 01 Jan 2021 31 Mar 2021 10-Q 14 Nov 2022
Q4 2020 -$1,259,590 -$452,022 -$450,472 -290.6% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022
Q3 2020 -$809,118 -$295,990 -$157,415 -1.1% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$651,703 -$260,396 -$143,579 -1.2% 01 Apr 2020 30 Jun 2020 10-Q 12 Nov 2021
Q1 2020 -$508,124 -$251,182 -$305,142 -5.7% 01 Jan 2020 31 Mar 2020 10-Q 12 Nov 2021
Q4 2019 -$202,982 -$1,550 +$1,216,067 +99.9% 29 Oct 2019 31 Dec 2019 10-K 06 Apr 2021
Q3 2019 -$1,419,049 -$138,575 +$217,412 +61.1% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$1,636,461 -$116,817 +$190,461 +62% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020
Q1 2019 -$1,826,922 $53,960 +$793,352 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$2,620,274 -$1,217,617 -$45,432 -3.9% 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020
Q3 2018 -$2,574,842 -$355,987 +$1,141,712 +76.2% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$3,716,554 -$307,278 +$660,207 +68.2% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019
Q1 2018 -$4,376,761 -$739,392 -$125,497 -20.4% 01 Jan 2018 31 Mar 2018 10-Q 19 Apr 2019
Q4 2017 -$4,251,264 -$1,172,185 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019
Q3 2017 -$1,497,699 -$1,065,175 -2.5% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$967,485 -$81,785 -9.2% 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018
Q1 2017 -$613,895 +$237,347 +27.9% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q3 2016 -$3,412,153 -$432,524 +$384,034 +47% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2016
Q2 2016 -$3,796,187 -$885,700 -$402,434 -83.3% 01 Apr 2016 30 Jun 2016 10-Q 04 Aug 2016
Q1 2016 -$3,393,753 -$851,242 -$699,443 -4.6% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2016
Q4 2015 -$2,694,310 -$1,242,687 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2016
Q3 2015 -$816,558 -$738,230 -9.4% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$483,266 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 -$151,799 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q3 2014 -$78,328 01 Jul 2014 30 Sep 2014 10-Q 21 Dec 2015

Sigyn Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$3,340,212 +$805,724 +19.4% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$4,145,936 -$1,216,119 -41.5% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 -$2,929,817 +$74,802 +2.5% 01 Jan 2022 31 Dec 2022 10-K 20 Feb 2024
2021 -$3,004,619 -$1,745,029 -1.4% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$1,259,590 +$1,815,100 +59% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022
2019 -$3,074,690 -$454,416 -17.3% 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2020
2018 -$2,620,274 +$1,630,990 +38.4% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020
2017 -$4,251,264 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019
2015 -$2,694,310 -$2,306,766 -6% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2016
2014 -$387,544 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.